Company Description
TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer.
The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma.
The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers.
TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.
| Country | United States |
| Founded | 2010 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 112 |
| CEO | Mary Szela |
Contact Details
Address: 6272 West 91st Avenue Westminster, Colorado 80031 United States | |
| Phone | 303 442 1222 |
| Website | trisaluslifesci.com |
Stock Details
| Ticker Symbol | TLSI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001826667 |
| CUSIP Number | 89680M101 |
| ISIN Number | US89680M1018 |
| Employer ID | 85-3009869 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Mary T. Szela B.S.N., M.B.A. | Chief Executive Officer, President and Director |
| Sean Edward Murphy | Chief Manufacturing, Strategy and Business Development Officer and Director |
| James E. Young | Chief Financial Officer |
| Lori Ann Santamaria | Vice President of Operations |
| Jennifer L. Stevens J.D. | Chief Regulatory Officer |
| Dr. Richard B. Marshak M.B.A., MBA, VMD | Chief Commercial Officer |
| Jodi Devlin | Chief of Clinical Strategy and Operations |
| Dr. Bryan F. Cox Ph.D. | Chief of Research |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 27, 2025 | 8-K | Current Report |
| Feb 25, 2025 | 8-K | Current Report |
| Feb 19, 2025 | 8-K | Current Report |
| Feb 3, 2025 | 8-K | Current Report |
| Jan 31, 2025 | 8-K | Current Report |
| Jan 23, 2025 | 8-K | Current Report |
| Jan 8, 2025 | 8-K | Current Report |
| Dec 30, 2024 | D | Notice of Exempt Offering of Securities |
| Dec 19, 2024 | SCHEDULE 13D/A | Filing |